Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 53 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant TumorsCompletedNCT05223231Phase 1/2
• Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerCompletedNCT05223088Phase 2
• Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT05221645Phase 2
• Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05220267Phase 2
• Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial CancerCompletedNCT05219435Phase 2
• FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRCCompletedNCT05217069Phase 2
• Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)CompletedNCT05216653Phase 2
• Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05215574Phase 1
• CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer ImmunotherapyActive, not recruitingNCT05215470Phase 2
• Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)Active, not recruitingNCT05215106Phase 2
• A Phase II Trial of AK104 in Advanced Non-Small Cell Lung CancerCompletedNCT05215067Phase 2
• A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of PatientsStatus unknownNCT05214976Phase 2
• A Study of AK112 in Advanced Malignant TumorsCompletedNCT05214482Phase 1/2
• The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCCCompletedNCT05213884Phase 2
• Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCCStatus unknownNCT05213312Phase 2/3
• Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC PatientsCompletedNCT05213221Phase 2
• A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCCWithdrawnNCT05212922Phase 2
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCActive, not recruitingNCT05211895Phase 3
• Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal CarcinomaActive, not recruitingNCT05211232Phase 3
• THIO Sequenced With Cemiplimab in Advanced NSCLCActive, not recruitingNCT05208944Phase 2
• Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain MetastasesStatus unknownNCT05207904Phase 2
• PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.Status unknownNCT05207735Phase 2
• Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic SubtypeTerminatedNCT05207709Phase 3
• Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)Active, not recruitingNCT05206812Phase 2
• Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI CancersActive, not recruitingNCT05205330Phase 1/2
• A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia AreataStatus unknownNCT05205070Phase 2
• Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal MetastasisStatus unknownNCT05204173Phase 2
• Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell TherapyWithdrawnNCT05204160Phase 2
• Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal CarcinomaActive, not recruitingNCT05201859Phase 2
• Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).Status unknownNCT05201612Phase 2
• Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First LineActive, not recruitingNCT05201547Phase 3
• Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Active, not recruitingNCT05201066Phase 2
• BAT7104 in Patients With Advanced Solid TumoursCompletedNCT05200013Phase 1
• A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabTerminatedNCT05199285Phase 2
• NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal CancerActive, not recruitingNCT05197322Phase 2
• A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant TumorsCompletedNCT05193721Phase 1
• Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal CancerStatus unknownNCT05193292Phase 2
• A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic SarcomaStatus unknownNCT05193214Phase 2
• Tislelizumab as Cross-line Treatment for Advanced NSCLCStatus unknownNCT05192681Phase 2
• A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT05192486Phase 1/2
• Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCCActive, not recruitingNCT05189730Phase 2
• First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate CancerActive, not recruitingNCT05189457Phase 2
• Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1
• Phase 3 Clinical Study of AK112 for NSCLC PatientsActive, not recruitingNCT05184712Phase 3
• A Phase 1/2 Study of BA3071 in Patients With Solid TumorsActive, not recruitingNCT05180799Phase 1/2
• Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyTerminatedNCT05180006Phase 2
• Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical CancerStatus unknownNCT05179317Phase 2
• Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast CancerWithdrawnNCT05177796Phase 2
• Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLCTerminatedNCT05176925Phase 2
• A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid TumorsCompletedNCT05176509Phase 1
• Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma PatientsActive, not recruitingNCT05176470Phase 1
• Avelumab, Palbociclib and Axitinib in Advanced RCCWithdrawnNCT05176288Phase 2
• Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.Active, not recruitingNCT05176002Phase 1/2
• Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA MeasurementsStatus unknownNCT05175235Phase 1/2
• Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/RearrangementsActive, not recruitingNCT05174650Phase 2
• Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell CarcinomaStatus unknownNCT05174325Phase 2
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)Active, not recruitingNCT05173987Phase 3
• A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid TumorsCompletedNCT05173142Phase 1/2
• A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid TumorsStatus unknownNCT05172856Phase 1
• A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid TumorsStatus unknownNCT05171790Phase 1
• Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal CancerActive, not recruitingNCT05171660Phase 3
• Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCCStatus unknownNCT05171309Phase 2
• Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung CancerWithdrawnNCT05171062Phase 1
• Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)CompletedNCT05169957Phase 1
• A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid TumorsCompletedNCT05169697Phase 1
• Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT05168618Phase 2
• Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular CarcinomaStatus unknownNCT05166772Phase 2
• HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTTCompletedNCT05166239Phase 2
• Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)CompletedNCT05165433Phase 1
• CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or RelapsedActive, not recruitingNCT05162976Phase 1
• Donafenib Plus Sintilimab for Advanced HCCCompletedNCT05162352Phase 2
• The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung CancerStatus unknownNCT05162196Phase 2
• Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT TrialWithdrawnNCT05161533Phase 2
• Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal CancerStatus unknownNCT05160727Phase 2
• Neoadjuvant Nivolumab for Upper Tract Urothelial CarcinomaStatus unknownNCT05160285Phase 2
• Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)CompletedNCT05159778Phase 2
• Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian CancerStatus unknownNCT05158062Phase 2
• Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLCStatus unknownNCT05157542Phase 1
• Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerActive, not recruitingNCT05156788Phase 2
• A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial CarcinosarcomaCompletedNCT05156268Phase 2
• Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid TumorsCompletedNCT05155722Phase 1
• Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial CarcinomaCompletedNCT05154994Phase 1
• Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract CancersWithdrawnNCT05153304Phase 1/2
• A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard TreatmentsActive, not recruitingNCT05152472Phase 2
• A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Phase 3
• A Study of Carilizumab Combined With Concurrent ChemoradiotherapyStatus unknownNCT05151549Phase 2
• KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.Active, not recruitingNCT05149326Phase 3
• Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCLStatus unknownNCT05149170Phase 2
• Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell CancerActive, not recruitingNCT05148546Phase 2
• A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid TumorTerminatedNCT05148442Phase 1
• A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaActive, not recruitingNCT05147558Phase 2
• Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid TumorsActive, not recruitingNCT05145907Phase 2
• A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian CancerStatus unknownNCT05145218Phase 3
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid TumorsStatus unknownNCT05145179Phase 1
• A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Active, not recruitingNCT05144854Phase 3
• Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine CarcinomasStatus unknownNCT05142865Phase 2
• A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabActive, not recruitingNCT05142696Phase 1/2
• A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue SarcomaStatus unknownNCT05138146Phase 2
• PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's LymphomaStatus unknownNCT05137886Phase 2
• A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the BladderActive, not recruitingNCT05137262Phase 2

← Immune Checkpoint Inhibitors overview